Pharma Focus Asia

Sanyou Bio and BioGeometry Team Up to Develop Innovative Antibody Drug Discovery Platform Driven by AIGC

Tuesday, March 19, 2024

BioGeometry and Sanyou Bio recently announced a strategic partnership agreement, signifying a significant collaboration in biotechnology.

BioGeometry, a digital biology pioneer, specializes in AI-driven protein design and research and development platforms. Sanyou Bio, on the other hand, is a prominent biotechnology enterprise focusing on innovative biologic drug research and services.

The partnership aims to leverage both companies' expertise in generative AI technology and practical drug development experience to create a next-generation antibody drug discovery platform driven by AI. They intend to collaborate with leading pharmaceutical companies to enhance the efficiency of new drug research and development.

Sanyou Bio will integrate BioGeometry's proprietary generative AI antibody design platform, GeoBiologics, into its operations. Both parties will invest to create an advanced Dry-Wet antibody R&D platform by merging BioGeometry's AI algorithm dry lab platform with Sanyou Bio's wet lab capabilities. This platform will facilitate the development of more large molecule drug pipelines and nurture innovative projects.

Sanyou Bio has established a high-throughput R&D platform for innovative antibody drugs, boasting the world's largest antibody library and cutting-edge technical resources. Their platform integrates various molecule generation technologies and automated screening processes, focusing on generating molecules with superior characteristics.

BioGeometry has developed geometric deep learning models that significantly reduce time and costs in antibody design. Their GeoBiologics platform facilitates a closed-loop between dry and wet lab experiments, enhancing efficiency in discovering functional molecules.

Dr. Guojun Lang, CEO of Sanyou Bio, expressed confidence in BioGeometry's AI technology to transform their R&D platform, enhancing their competitiveness in new drug discovery.

Dr. Jian Tang, CEO of BioGeometry, emphasized the joint creation of a cutting-edge AI-enabled antibody discovery platform with Sanyou Bio, aiming to revolutionize new drug R&D and accelerate advancements in antibody drug research.

In summary, the strategic partnership between BioGeometry and Sanyou Bio marks a new era of collaboration in biotechnology, with a focus on innovation and efficiency in drug discovery and development.

 

Source: prnewswire.com

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference